114 results about "Specific immunity" patented technology

The invention discloses a toxoplasma gondii attenuated vaccine strain RH delta rop67 as well as a construction method and application thereof, and belongs to the technical field of parasitic disease prevention and control and biological product preparation. The attenuated vaccine strain is constructed by performing targeted knockout on the ROP67 gene in a toxoplasma gondii strain RH delta ku80 through a CRISPR / Cas9 mediated gene editing technology. Compared with a wild type strain, the attenuated vaccine strain shows remarkable attenuation characteristic and good immunogenicity. A test result shows that the attenuated vaccine strain can induce a host to generate specific immune response mainly based on cellular immunity, maintains a protection effect on toxoplasma gondii infection in a relatively long immune period, and has a protection effect on tachyzoite infection and a chronic infection stage of toxoplasma gondii strains with different virulence; the survival ability of a host to tachyzoite infection can be improved, and the formation level of cysts in tissues is reduced. The invention provides a technical scheme with long-term immune potential for research and development of toxoplasma gondii attenuated vaccines.

This invention discloses a recombinant adenovirus vaccine targeting the Tp0326 antigen and its preparation method, comprising a recombinant adenovirus vector and the Tp0326 antigen expressed therein. The recombinant adenovirus vector uses a replication-defective human adenovirus type 5 (Ad5) as a backbone, inserting the full-length Tp0326 antigen gene of *Treponema pallidum* into the adenovirus shuttle vector pshuttle-IRES-rGFP-1, and obtaining it through homologous recombination with the adenovirus backbone plasmid pAdEasy-1. This invention, using a replication-defective Ad5 as a vector, provides a recombinant adenovirus vaccine with high safety and efficient expression of the full-length Tp0326 antigen. The expressed antigen has a natural conformation, retains the ECL4 immunodominant epitope, and is more likely to induce a specific immune response, resulting in stronger immunogenicity. The preparation method involves constructing a recombinant adenovirus vector through homologous recombination, packaging it in HEK293T cells, and purifying it by CsCl density gradient centrifugation to obtain a high-purity, high-titer recombinant adenovirus vaccine suitable for large-scale production. The recombinant adenovirus vaccine can be administered via intramuscular or intranasal injection.

The invention provides a three-specificity immune cell adapter-cytokine fusion protein for malignant tumor immunotherapy as well as a preparation method and application of the three-specificity immune cell adapter-cytokine fusion protein. The fusion protein comprises a first binding domain, a second binding domain and a cytokine structural domain which are covalently linked to form a single polypeptide chain or polypeptide compound. The first binding domain is specifically bound with a tumor associated antigen, and the target spot of the first binding domain comprises but is not limited to KK-LC-1, MSLN, HER2, Claudin18.2, Claudin6 and PSMA; the second binding domain is specifically bound with a CD3 protein complex on the surface of the T cell; the cytokine domain is IL2, IL15, IL12, IL21 or a functional variant thereof. The invention also relates to a nucleic acid molecule for coding the fusion protein, an expression vector and application thereof. The fusion protein can be used for immunotherapy of malignant tumors such as colon cancer, gastric cancer, breast cancer, liver cancer, lung cancer and cervical cancer, and has a good application prospect. The invention effectively solves the problems of insufficient T cell activation and limited killing in solid tumor immunotherapy in the prior art.

The present invention provides methods, compositions, systems, and kits comprising nano-satellite complexes and / or serum albumin carrier complexes, which are used for modulating antigen-specific immune response (e.g., enhancing anti-tumor immunity). In certain embodiments, the nano-satellite complexes comprise: a) a core nanoparticle complex comprising a biocompatible coating surrounding a nanoparticle core; b) at least one satellite particle attached to, or absorbed to, the biocompatible coating; and c) an antigenic component conjugated to, or absorbed to, the at least one satellite particle component. In certain embodiments, the complexes further comprise: d) a type I interferon agonist agent. In some embodiments, the serum albumin complexes comprise: a) at least part of a serum albumin protein, b) an antigenic component conjugated to the carrier protein, and c) a type I interferon agonist agent.

The invention relates to the field of animal nutrition additives, and particularly discloses an animal additive based on probiotic synergistic fermentation sea buckthorn residue and hermetia illucens protein and a preparation method thereof, the animal additive comprises the following components by mass: 5%-10% of a filling auxiliary material, and the balance of a fermentation composite product; the sea-buckthorn residues and the hermetia illucens larvae can be fermented to form a double-substrate fermentation product, so that the double-substrate fermentation product has a synergistic nutrition effect, and can be used for remarkably promoting the weight gain condition of animals, improving spleen and thymus indexes and increasing serum IgG and IgM; the hermetia illucens protein is rich in lauric acid, antibacterial peptide and high-quality animal protein, so that the non-specific immunity and the anti-stress capability of an organism are enhanced, and the infection risk in the breeding process is reduced; the low-value sea-buckthorn residues and the hermetia illucens larvae are upgraded and converted into high-value feeding resources in a biological fermentation mode, the environmental pressure of processing by-products is relieved, the additional value of raw materials is increased, and the method conforms to resource circulation and environmental protection policy guidance.

In various embodiments tolerogenic nanoparticles are provided that induce immune tolerance to one or more desired antigen(s) and / or that reduce an immune response to those antigen(s). In certain embodiments the tolerogenic nanoparticle comprises a nanoparticle comprising a biocompatible polymer; an antigen disposed within or attached to said biocompatible polymer where said antigen comprises an antigen to which immune tolerance is to be induced by administration of said tolerogenic nanoparticle to a mammal; and a first targeting moiety that binds to a scavenger receptor in the liver, and / or a second targeting moiety that binds to a mannose receptor in the liver, and / or a third targeting moiety that binds to hepatocytes, wherein said first and / or second and / or third targeting moiety are attached to the surface of said nanoparticle.

Provided is a pharmaceutical composition for use in inducing an antigen-specific immune response, the pharmaceutical composition comprising: a polyrotaxane having a plurality of macroring molecules, an axis molecule that penetrates the rings of the macroring molecules, and caps that bind to the ends of the axis molecule, in which at least some of the macroring molecules include an amine-containing group having a monovalent proton at neutral pH and a divalent proton at acidic pH; and an antigen.

This invention discloses the application of arginine-depleted engineered bacteria for the treatment of soft tissue sarcomas, including preliminary validation, obtaining qualified engineered bacteria SGR1, obtaining drug compositions and regimens, experimental conclusions, and clinical application promotion. During use, clinical soft tissue sarcoma samples are collected, including undifferentiated pleomorphic sarcoma, synovial sarcoma, and liposarcoma. Immunohistochemistry (IHC) is used to detect ASS1 protein expression, qPCR is used to detect ASS1 gene transcription levels, and the proportion of ASS1 deletion / low expression is statistically analyzed. Arginine auxotrophic sarcoma subpopulations are confirmed based on literature. Cells are cultured in arginine-containing or arginine-free media, and cell viability, colony formation, cell cycle, and apoptosis are detected. The sensitivity of ASS1-deficient cells to arginine deprivation is verified, and therapeutic targets are identified. The enzyme activity, substrate specificity, and immunogenicity of human ARG I / II, mycoplasma ADI, and Pseudomonas ADI are compared. High-activity, low-immunogenic enzymes or enzyme combinations (such as human ARG I + microbial ADI) are selected, and site-directed mutagenesis or codon optimization is performed on microbial ADI to increase expression levels.

The invention discloses a CD176 oral vaccine immunologic adjuvant and an application thereof, the CD176 oral vaccine immunologic adjuvant comprises a lucid ganoderma component, and the lucid ganoderma component is used as the immunologic adjuvant, so that the immune efficacy of an oral CD176 vaccine can be remarkably enhanced, the specific immune response is improved and enhanced, and more effective immune protection is provided for an organism.

The present invention relates to the therapeutic use of non-classical human major histocompatibility complex (MHC) molecules (also known as MHC class Ib molecules) in combination with a peptide antigen for the treatment of neuromyelitis optica (NMO). More specifically, the present invention relates to recombinant polypeptides comprising a peptide antigen in combination with one or more domains of a non-classical MHC class Ib molecule. The present invention also relates to methods of producing such recombinant polypeptides, pharmaceutical compositions comprising such recombinant polypeptides, and their use in the treatment of neuromyelitis optica (NMO).

The present invention relates to a combined treatment composition for tumor treatment and a combined treatment method. The combined treatment composition or a medicine kit comprises a therapeutically effective amount of a platinum chemotherapeutic drug, and a therapeutically effective amount of CpG oligonucleotide and a therapeutically effective amount of R848. The present invention further provides a combined treatment method for treating a tumor by means of the combined treatment composition or the medicine kit. Firstly, a low-dose chemotherapeutic drug is used to kill a tumor so as to release a tumor neoantigen, such that a body immune system autonomously identifies and screens the neoantigen, and then CpG oligonucleotide and an R848 activator of immune response are used to induce and promote the body to generate immune response specific to the tumor neoantigen, such that the anti-tumor function of T cells is improved and enhanced, thereby achieving the effect of inhibiting tumor growth.

The present invention provides Claudin-6-specific immunoreceptors (T cell receptors and artificial T cell receptors (chimeric antigen receptors; CARs)) and T cell epitopes which are useful for immunotherapy.

This article provides a CD79b antibody and a CD79b-specific chimeric antigen receptor (CAR). Further, this article provides immune cells expressing the CD79b-specific CAR and a method for treating cancer by administering the CD79b-specific CAR immune cells.

The present invention relates to means and methods to prevent and / or treat Epstein-Barr virus (EBV) and EBV-induced diseases, such as EBV infection, infectious mononucleosis (IM), malignant or non-malignant post-transplant lymphoproliferative disorder (PTLD) and other EBV-associated diseases. In particular, the invention provides a SQAPLPCVL peptide that can be used in a treatment or a method of treatment to induce an EBV-specific immune response in a subject. The SQAPLPCVL can be used in a treatment or method of treatment as a vaccine against EBV and EBV-induced diseases. It is preferred herein that Epstein-Barr virus (EBV) and / or EBV-induced diseases are prevented.

The invention discloses a toxoplasma gondii gene deletion strain ME49 [delta] TGZS and an application thereof in preparation of a gene engineering inactivated vaccine. The toxoplasma gondii gene deletion strain ME49 [delta] TGZS is prepared by taking a toxoplasma gondii strain ME49 as a parent strain and knocking out a TGZS gene in the toxoplasma gondii strain ME49; the nucleotide sequence of the TGZS gene is as shown in SEQ ID NO: 1. The strain can maintain normal polypide growth and replication capacity under an in-vitro culture condition, after inactivation treatment, the strain loses proliferative activity but maintains a complete polypide morphological structure, and the strain is compatible with an aluminum hydroxide adjuvant to prepare a vaccine preparation. According to the vaccine, by activating the specific immune response of a terminal host cat, the sexual reproduction cycle of the toxoplasma gondii in the intestinal epithelial cells of the cat is effectively blocked, and the formation and discharge of oocysts are remarkably inhibited, so that the propagation chain of the toxoplasma gondii is controlled from the source. The invention provides a new effective means for prevention and control of toxoplasmosis.

Multi-specific immune cell engaging molecules are provided herein. These immune cell engaging molecules bind cancer cells co-expressing CD19 and CD33 while also binding immune cells, allowing the immune cells to recognize and destroy the CD19 and CD33-expressing cancer cells.

The present disclosure provides a microemulsion-based vaccine delivery system, and further provides a preparation method and an application thereof. Using the microemulsion absorbing a series of metal ion compounds, and adding an antigen in a preparation process, antigen entrapment can be realized and a stable vaccine preparation is obtained. The prepared vaccine can effectively be taken up by an antigen-presenting cell and effectively delivered to lymph nodes to induce an antigen-specific immune response, and the same has a wide application prospect.

The present disclosure describes methods, compositions, and kits related to the combination of a TLR7 modulating compound and an HIV vaccine. The combination can be used in a method of treating or preventing an HIV infection in a human.

The present invention relates to a vaccine composition comprising a recombinant Nipah virus protein. The vaccine composition according to the present invention not only exhibits excellent immunogenicity against both the G protein and the F protein of Nipah virus, but also exhibits immunogenicity against the G protein and the F protein of Hendra virus, and thus can be used as a universal vaccine against Henipavirus. In addition, the vaccine composition has the characteristic of inducing cell-mediated immune responses, and therefore can be provided as a formulation for enhancing specific immune responses to an administered drug such as an adjuvant or a vaccine.

The invention provides a feed additive capable of improving the antibacterial ability of haliotis diversicolor and a preparation method and application thereof.The preparation method of the feed additive comprises the steps that an ulva lactuca raw material is properly treated, polysaccharide components in the ulva lactuca raw material are extracted, and the obtained ulva lactuca polysaccharide is scientifically proportioned and mixed with a proper feed carrier and other nutritional ingredients; after the feed additive is fed, the ulva polysaccharide can play a role in the abalone body, enhance the non-specific and specific immune response of the abalone and improve the removal capacity of vibrio alginolyticus, so that diseases caused by pathogenic bacteria are effectively prevented and controlled, and the morbidity and mortality in the abalone culture process are reduced. By using the feed additive disclosed by the invention, the health condition and the growth performance of abalones can be improved, the use amount of antibiotics is reduced, the culture risk and the environmental pollution are reduced, the quality and the safety of abalone products can also be improved, and the feed additive has important practical significance and popularization value for promoting the sustainable development of the abalone culture industry.

The invention is applicable to the field of gene engineering, and provides a mycobacterium tuberculosis ESAT-6-LS protein nanoparticle, a preparation method and application thereof, the mycobacterium tuberculosis ESAT-6-LS protein nanoparticle is formed by sequence fusion of mycobacterium tuberculosis ESAT-6 protein and LS protein, and the amino acid sequence of the mycobacterium tuberculosis ESAT-6-LS protein nanoparticle is shown as SEQ ID NO: 2 in a sequence table. The ESAT-6-LS protein nanoparticle provided by the invention is non-toxic and free of pathogenicity, can ensure that a vaccine has good biological safety, and is suitable for clinical application. Animal experiments show that after a mouse is immunized by the ESAT-6-LS protein nanoparticle, strong humoral immunity (antibody generation) and cellular immunity (T cell response) can be stimulated at the same time, and it is proved that the recombinant ESAT-6-LS protein nanoparticle vaccine can effectively induce specific immune protection.

The application discloses a hybridoma cell strain secreting monoclonal antibody PVY-5, the monoclonal antibody and application, the hybridoma cell strain 4B4D8C3 can secrete anti-potato Y virus monoclonal antibody, the preservation number of the hybridoma cell strain is CCTCC NO: C2022282, the monoclonal antibody PVY-5 has specific immunoreaction with the coat protein of potato Y virus, the heavy chain variable region amino acid sequence of the monoclonal antibody PVY-5 is as shown in SEQ ID NO.6, the light chain variable region amino acid sequence is as shown in SEQ ID NO.7, the sensitivity reaches 1:5120 times dilution by using direct ELISA method detection to the leaf of potato Y virus disease infection, the monoclonal antibody PVY-5 can also be used to prepare ELISA kit, or colloidal gold kit, or nano analog enzyme kit, and the potato Y virus disease can be detected quickly, sensitively, economically and accurately.

This disclosure relates to KRAS immunogenic peptides and their uses. According to this disclosure, the KRAS immunogenic peptides selectively bind to MHC class II in a preferential mode to selectively enhance the immunogenicity of specific immune cells capable of killing cancer cells, and thus can be advantageously used as superior cancer vaccines for the prevention and / or treatment of cancer by minimizing immune escape mechanisms of cancer cells.

This invention relates to the field of biomedical technology, specifically disclosing a biomimetic exosome derived from tumor cell membranes, its preparation method, and its applications. The preparation method of the biomimetic exosomes derived from tumor cell membranes provided by this invention includes the following steps: mixing LLC-derived cell membranes with doxorubicin and resveratrol solutions, and preparing biomimetic exosomes derived from tumor cell membranes by extrusion. The preparation method provided by this invention has advantages such as wide availability of raw materials, simple and controllable process, low technical threshold, and suitability for industrial-scale production. The biomimetic exosomes provided by this invention can effectively induce a specific immune response against tumor cells, achieving the purpose of inhibiting the progression of primary tumors and prolonging the survival of tumor-bearing mice. It can also promote the polarization of macrophages from a pro-tumor M2 phenotype to an anti-tumor M1 phenotype, laying a favorable foundation for the efficient implementation of subsequent immunotherapy and possessing broad application prospects.

The present disclosure relates to multispecific molecules comprising a peptide-MHC complex and an immune cell antigen targeting moiety. Particular embodiments relate to multimeric (e.g., dimeric) molecules comprising a peptide-MHC complex, an immune cell antigen targeting moiety, and a multimerization moiety. The present disclosure further provides pharmaceutical compositions comprising the multispecific molecules, and methods of using the multispecific molecules in antigen-specific T cell activation, in inducing antigen-specific immune responses, and in therapeutic applications, as well as nucleic acids encoding the multispecific molecules, recombinant cells expressing the multispecific molecules, and methods of producing the multispecific molecules.

A bispecific immunotherapeutic protein and methods of use and production thereof are disclosed wherein the immunotherapeutic protein comprises one or more immunoglobulin heavy chain polypeptides comprising an Fc region component comprising at least one constant heavy chain domain 3 (CH3) (or at least one constant heavy domain 4 (CH4) domain), wherein the one or more polypeptides comprise an amino acid substitution (Eu numbering) located at a position corresponding to H429 of the amino acid sequence of the human IgG1 heavy chain.

The present application relates to the field of immunoassay technology, discloses a product for early diagnosis of sepsis and its application, the composition of the product for early diagnosis of sepsis includes detecting SAA1 protein and PDL1 + The product for detecting the content of exosome in sample is based on antigen-antibody specific immune binding to detect SAA1 protein and PDL1 + The product for detecting the content of exosome in sample, the detection method adopted by the detection product is selected from one of fluorescence immunoassay, enzyme-linked immunosorbent assay, colloidal gold immunochromatography, chemiluminescence immunoassay, electrochemical immunoassay and nanopore-based immunosensing detection method, the product for early diagnosis of sepsis improves the accuracy of early diagnosis of sepsis and disease condition evaluation in a double-index cooperative manner, effectively solves the technical bottleneck that the existing sepsis detection method is insufficient in sensitivity, poor in specificity and difficult to meet the requirements of early precise diagnosis and dynamic disease condition evaluation.

Provided herein include new antibodies reactive for canine CD3, which are shown to substantially increase activation of canine T cells; new multi-specific immune cell engager molecules based on the canine CD3 antibodies, which are shown to effectively bind canine cancer antigens and recruit T cells for killing of the cancer cells; as well as new recombinant proteins derived from canine cartilage protein fragments and hydrogels thereof. Uses of these compositions are also provided, which include therapeutic uses of antibodies and multi-specific immune cell engager molecules for treatment of cancers or other diseases in dogs, as well as uses of hydrogels for local immunotherapy delivery for reduction of post-surgical recurrence risk, reduction of cancer at surgically inoperable sites, provision of palliation, and / or substitution for surgery.

The application provides a hybridoma cell strain secreting a monoclonal antibody against a alginate mannuronic acid tetrasaccharide epitope, a monoclonal antibody and application. In order to enhance the immunogenicity of the mannuronic acid tetrasaccharide, a glycoconjugate KLH-1 is used as an immunogen to inject and immunize a mouse, so that the mouse is stimulated to produce a specific immune response against the mannuronic acid tetrasaccharide epitope, then spleen cells of the immunized mouse are fused with myeloma cells, and after screening, an initial hybridoma cell strain is obtained; then after subcloning and specific screening, a hybridoma cell strain capable of stably secreting a monoclonal antibody of the target mannuronic acid tetrasaccharide epitope in alginate is obtained, and a monoclonal ascites antibody is further obtained. The monoclonal ascites antibody shows specific recognition and combination ability for pseudomonas aeruginosa, and the combination activity is related to the expression level of alginate on the surface of the bacteria. Therefore, the monoclonal ascites antibody can be used as a precise detection and diagnosis tool for pseudomonas aeruginosa, and can also be applied to the antibacterial treatment of pseudomonas aeruginosa infection.